Prostate Cancer

Quoc-Dien Trinh, MD, discusses the impact of the COVID-19 pandemic on prostate cancer treatment and factors that are considered to inform treatment decisions.

Cell-free DNA–based androgen receptor locus alterations and enhancers correlated with metastatic prostate cancers determined to be resistant to AR-targeted therapies.

Luteinizing hormone-releasing hormone agonists were found to often be administered later than the scheduled dosing used in patients with prostate cancer on pivotal clinical trials, leading to late testosterone values being greater than 20 ng/dL and the mean testosterone level almost doubling castration level.

In prostate cancer, investigators have revealed a link between disease progression and the severity of splicing dysregulation, as well as establishing intron retention as an indicator of prostate cancer stemness and aggressiveness.

The PARP inhibitor olaparib is now available for patients with metastatic castration-resistant prostate cancer whose tumors harbor mutations in homologous recombination repair genes.

Atish D. Choudhury, MD, PhD, sheds light on the nonmetastatic castration-resistant prostate cancer treatment landscape and notable ongoing trials examining antiandrogens in different settings.

Numerous analyses conducted over the past few years have underscored a serious issue in clinical cancer trials that needs to be addressed: a lack of racial and ethnic diversity among participants.

Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.

Rana R. McKay, MD, discusses the benefit of intense neoadjuvant hormone therapy prior to radical prostatectomy in men with high-risk prostate cancer and next steps for research.

Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.

Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Fred Saad, MD, FRCS, discusses the impact of apalutamide on nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN trial.

Neal D. Shore, MD, FACS, discusses the cardio-oncology strategies that can be implemented in patients with prostate cancer to reduce the chances of a cardio-related adverse-event.

The FDA has provided regulatory clarity on the design of the pivotal phase 3 trial examining the first-in-class oral, oral, selective antitubulin agent VERU-111 in the treatment of patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Andrei Gafita, MD, discusses available therapies for men with advanced castration-resistant prostate cancer.

The administration of luteinizing hormone-releasing hormone agonists in patients with prostate cancer was significantly more delayed in clinical practice than in pivotal clinical trials.

Findings from a recent study published in European Urology show that salvage lymph node dissection alone is inadequate intervention for patients with prostate cancer and nodal recurrence.

Thomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.

Neal Shore, MD, discusses the significantly improved overall survival in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.